Track topics on Twitter Track topics that are important to you
Certara is dedicated to improving human health through a broad spectrum of software products and services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. Certara unites Tripos (www.tripos.com) and Pharsight Corporation (www.pharsight.com). Tripos provides innovative scientific software solutions and services enabling life science researchers to improve the efficiency of molecular discovery. Pharsight provides software and consulting services to improve productivity and decision-making in preclinical and clinical drug development.
The EQT VII fund has agreed to acquire Certara, a provider of technology-driven decision support solutions for drug development, for an enterprise value of $850 million. The company is being acquired...
MTPConnect (the Medical Technologies and Pharmaceuticals Industry Growth Centre) will provide a proposed AUD750,000 provisional funding to the Certara–Monash University Industry Fellowship Progr...
EQT's acquisition of Certara is a bet on the continued convergence of healthcare and technology as the industry further adopts biosimulation to advance drug development.
Certara, a global provider of model-informed drug development and regulatory science, announced that Andreas Wallnöfer, Ph.D., has joined the company as a senior executive advisor, providing consulti...
(Reuters) - Private equity firm EQT said on Tuesday it has agreed to acquire U.S. drug development consultancy Certara for $850 million, including debt, from Arsenal Capital Partners, another buyout f...
Certara, a global provider of model-informed drug development and regulatory science, announced the launch of Phoenix 8.0. Phoenix is the most advanced, intuitive, and widely-used software for pharmac...
Arsenal Capital Partners has announced it is selling its portfolio company, Certara, to EQT VII Fund for $850 million, although, as a part of the deal, it will retain a minority ownership stake.
Certara, the global leader in model─informed drug development and regulatory science, announced that the US Food and Drug Administration (FDA) has granted approval for expanded use of its PBPK Simcy...
Certara is dedicated to improving human health through a broad spectrum of software products and services, from molecular discovery through clinical development, with special focu...
Pharsight, A Certaraâ¢ Company, is a market-leading provider of software products and scientific consulting services to help pharmaceutical and biotechnology companies improve...
Tripos, a Certaraâ¢ Company, is a global leader in innovative scientific software products and services enabling life science researchers to improve the efficiency of molecula...
Pharsight, a Certaraâ¢ company, is a market-leading provider of software products and scientific consulting services to help pharmaceutical and biotechnology companies improve...
We have published hundreds of Certara news stories on BioPortfolio along with dozens of Certara Clinical Trials and PubMed Articles about Certara for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Certara Companies in our database. You can also find out about relevant Certara Drugs and Medications on this site too.
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...